Role of transmembrane protein 33 in tumorigenesis and development

doi:10.16352/j.issn.1001-6325.2025.02.0258

Abstract

Abstract: Transmembrane protein 33 (TMEM33) is up-regulated in the majority of cancers. To change the expression of TMEM33 can significantly affect the proliferation, migration, and invasion of renal and cervical cancer cells. Its mechanisms of action may involve four aspects: 1)participation in lipid metabolism; 2)regulation of endoplasmic reticulum; 3)regulation of intracellular calcium homeostasis; 4) participation in angiogenesis.

Key words: transmembrane protein 33, tumor development, tumor metastasis, biomarker, therapeutic target

CLC Number:

R363.1

LOU Haijun, MENG Menggen, ZHANG Zhenyu, TONG Zhuoyun, WUDU Muli. Role of transmembrane protein 33 in tumorigenesis and development[J]. Basic & Clinical Medicine, 2025, 45(2): 258-262.

References 17

[1]	董晶, 商双, 高蜀君, 等. RNA干扰 TMEM33 的表达对宫颈癌细胞生长的影响[J].复旦学报(医学版),2023,50: 159-165.
[2]	Zhang J, Lu Q, Pang H, et al. miR-103a-3p aggravates renal cell carcinoma by targeting TMEM33[J]. Am J Transl Res, 2021,13: 12694-12703.
[3]	Huang Z, Li J, Du S, et al. Fkbp14 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome[J]. Oncotarget, 2016, 7: 39872-39884.
[4]	Venkataramani V, Yang Y, Schubert MC, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion[J]. Cell, 2022, 185: 2899-2917.
[5]	Liu F, Ma M, Gao A, et al. PKM2-TMEM33 axis regulates lipid homeostasis in cancer cells by controlling scap stability[J]. EMBO J, 2021, 40: e108065. doi:10.15252/embj.2021108065.
[6]	Perez CM, Felty Q. Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions[J]. Microvasc Res, 2022, 141: 104337. doi:10.1016/j.mvr.2022.104337.
[7]	Suliman HB, Healy Z, Zobi F, et al. Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis[J]. iScience, 2022, 25: 103535. doi:10.1016/j.isci.2021.103535.
[8]	Li H, Niu N, Yang J, et al. Nuclear respiratory factor 1 protects H9c2 cells against hypoxia-induced apoptosis via the death receptor pathway and mitochondrial pathway[J]. Cell Biol Int, 2021, 45: 1784-1796.
[9]	Sakabe I, Hu R, Jin L, et al. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling[J]. Breast Cancer Res Treat, 2015, 153: 285-297.
[10]	Chao X, Wang S, Fulte S, et al. Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mtorc1 activation and defective autophagy[J]. J Hepatol, 2022, 76: 639-651.
[11]	Tao M, Liu T, You Q, et al. P62 as a therapeutic target for tumor[J].Eur J Med Chem. 2020;193:112231. doi:10.1016/j.ejmech.2020.112231.
[12]	Zhang X, Dai M, Li S, et al. The emerging potential role of p62 in cancer treatment by regulating metabolism[J]. Trends Endocrinol Metab, 2023, 34: 474-488.
[13]	Nowak KL, Hopp K. Metabolic reprogramming in auto-somal dominant polycystic kidney disease: evidence and therapeutic potential[J]. Clin J Am Soc Nephrol, 2020, 15: 577-584.
[14]	Ghalehbandi S, Yuzugulen J, Pranjol MZI, et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF[J]. Eur J Pharmacol, 2023, 949: 175586.doi: 10.1016/j.ejphar.2023.175586.
[15]	Lu LF, Zhang C, Li ZC, et al. A novel role of zebrafish tmem33 in negative regulation of interferon production by two distinct mechanisms[J]. PLoS Pathog, 2021, 17: e1009317. doi:10.1371/journal.ppat.1009317.
[16]	Zhang D, Vjestica A, Oliferenko S. The cortical ER network limits the permissive zone for actomyosin ring assembly[J]. Curr Biol, 2010, 20: 1029-1034.
[17]	Tsai PL, Cameron CJF, Forni MF, et al. Dynamic quality control machinery that operates across compartmental borders mediates the degradation of mammalian nuclear membrane proteins[J]. Cell Rep, 2022, 41: 111675. doi:10.1016/j.celrep.2022.111675.